Region: Global
Category: Life Sciences

Global Life Sciences

(44,979 reports matching your criteria)
  • Drug Discovery Informatics

    ... at a CAGR of 9.6% over the analysis period 2024-2030. Drug Discovery Informatics Software, one of the segments analyzed in the report, is expected to record a 8.9% CAGR and reach US$3.4 Billion by the ... Read More

  • Electrophysiology Devices

    ... CAGR of 8.1% over the analysis period 2024-2030. Electrophysiology Ablation Catheters, one of the segments analyzed in the report, is expected to record a 9.3% CAGR and reach US$6.6 Billion by the end of the ... Read More

  • Paper Diagnostics

    ... CAGR of 6.6% over the analysis period 2024-2030. Lateral Flow Assay Kits, one of the segments analyzed in the report, is expected to record a 6.2% CAGR and reach US$6.7 Billion by the end of ... Read More

  • Pectin

    ... 5.0% over the analysis period 2024-2030. Food & BeverageEnd-Use, one of the segments analyzed in the report, is expected to record a 5.8% CAGR and reach US$904.0 Million by the end of the analysis period. ... Read More

  • Point-of-Care/Rapid Diagnostics

    ... CAGR of 7.5% over the analysis period 2024-2030. Other POC Products, one of the segments analyzed in the report, is expected to record a 6.0% CAGR and reach US$3.3 Billion by the end of the ... Read More

  • Protein Purification and Isolation

    ... 2030, growing at a CAGR of 8.7% over the analysis period 2024-2030. Protein Purification & Isolation Consumables, one of the segments analyzed in the report, is expected to record a 9.0% CAGR and reach US$10.3 ... Read More

  • Protein Supplements

    ... CAGR of 6.3% over the analysis period 2024-2030. Animal-Based Supplements, one of the segments analyzed in the report, is expected to record a 6.2% CAGR and reach US$22.5 Billion by the end of the analysis ... Read More

  • Radiation Dose Management

    ... at a CAGR of 13.7% over the analysis period 2024-2030. Radiation Dose Management Solutions, one of the segments analyzed in the report, is expected to record a 14.0% CAGR and reach US$479.6 Million by the ... Read More

  • Refurbished Medical Equipment

    ... at a CAGR of 11.1% over the analysis period 2024-2030. Medical Imaging Equipment, one of the segments analyzed in the report, is expected to record a 12.3% CAGR and reach US$13.3 Billion by the end ... Read More

  • RFID Blood Monitoring Systems

    ... 2030, growing at a CAGR of 5.5% over the analysis period 2024-2030. RFID Systems, one of the segments analyzed in the report, is expected to record a 5.7% CAGR and reach US$132.2 Million by the ... Read More

  • Rotary Pumps

    ... CAGR of 5.3% over the analysis period 2024-2030. Gear Pumps, one of the segments analyzed in the report, is expected to record a 6.2% CAGR and reach US$3.7 Billion by the end of the analysis ... Read More

  • Self-Care Medical Devices

    ... at a CAGR of 4.5% over the analysis period 2024-2030. Blood Glucose Monitors, one of the segments analyzed in the report, is expected to record a 5.6% CAGR and reach US$34.8 Billion by the end ... Read More

  • Sleep Apnea Oral Appliances

    ... 2030, growing at a CAGR of 15.5% over the analysis period 2024-2030. Mandibular Advancement Devices (MAD), one of the segments analyzed in the report, is expected to record a 16.5% CAGR and reach US$880.0 Million ... Read More

  • Sterile Medical Packaging

    ... at a CAGR of 7.3% over the analysis period 2024-2030. Plastics Material, one of the segments analyzed in the report, is expected to record a 8.3% CAGR and reach US$36.5 Billion by the end of ... Read More

  • Dietary Supplements

    ... CAGR of 7.4% over the analysis period 2024-2030. Vitamins Ingredient, one of the segments analyzed in the report, is expected to record a 8.4% CAGR and reach US$138.9 Billion by the end of the analysis ... Read More

  • Surgical Blades

    ... CAGR of 3.8% over the analysis period 2024-2030. Sterile Surgical Blades, one of the segments analyzed in the report, is expected to record a 3.9% CAGR and reach US$189.4 Million by the end of the ... Read More

  • Surgical Microscopes

    ... CAGR of 7.8% over the analysis period 2024-2030. Hospital End-Use, one of the segments analyzed in the report, is expected to record a 7.2% CAGR and reach US$927.5 Million by the end of the analysis ... Read More

  • Surgical Instrument Tracking Systems

    ... 2030, growing at a CAGR of 15.8% over the analysis period 2024-2030. Surgical Instrument Tracking Software, one of the segments analyzed in the report, is expected to record a 14.7% CAGR and reach US$337.6 Million ... Read More

  • Surgical Scalpels

    ... CAGR of 3.6% over the analysis period 2024-2030. Standard Scalpels, one of the segments analyzed in the report, is expected to record a 3.4% CAGR and reach US$518.7 Million by the end of the analysis ... Read More

  • Surgical Sutures

    ... CAGR of 5.4% over the analysis period 2024-2030. Suture Thread, one of the segments analyzed in the report, is expected to record a 5.6% CAGR and reach US$4.3 Billion by the end of the analysis ... Read More

  • Systemic Lupus Erythematosus (Sle) Drugs

    ... Million by 2030, growing at a CAGR of 6.4% over the analysis period 2024-2030. The U.S. Market is Estimated at US$68.0 Million While China is Forecast to Grow at 6.1% CAGR The Systemic Lupus Erythematosus ... Read More

  • Hydrophilic Coatings

    ... CAGR of 5.5% over the analysis period 2024-2030. Polymers Substrate, one of the segments analyzed in the report, is expected to record a 6.1% CAGR and reach US$7.6 Billion by the end of the analysis ... Read More

  • Hydrophobic Interaction Chromatography

    ... at a CAGR of 6.3% over the analysis period 2024-2030. Resins, one of the segments analyzed in the report, is expected to record a 7.3% CAGR and reach US$263.1 Million by the end of the ... Read More

  • Immunohematology Analyzers and Reagents

    ... 2030, growing at a CAGR of 4.7% over the analysis period 2024-2030. Immunohematology Reagents, one of the segments analyzed in the report, is expected to record a 4.2% CAGR and reach US$2.3 Billion by the ... Read More

  • Immunotherapy Drugs

    ... CAGR of 9.6% over the analysis period 2024-2030. Monoclonal Antibodies, one of the segments analyzed in the report, is expected to record a 9.7% CAGR and reach US$254.4 Billion by the end of the analysis ... Read More

Research Assistance

Live help

Join Alert Me Now!

Sign Up

Find out more on our blog
Cookie Settings